Albiglutide Peptide: Tanzeum, Eperzan, the Withdrawn Weekly GLP-1

Albiglutide is a peptide drug with an unusual story: it was a fully approved, once-weekly GLP-1 receptor agonist that performed well in a large cardiovascular outcomes trial, and yet it no longer exists on the market. Sold as Tanzeum in the United States and Eperzan in Europe, it was voluntarily withdrawn worldwide by its manufacturer in 2018.

That makes albiglutide a useful case study rather than a current treatment option. It shows how a peptide can be scientifically validated and commercially discontinued at the same time. It also belongs to one of the most discussed drug families today, the GLP-1 receptor agonists, so understanding why it disappeared helps put the surviving members of that class in context.

This guide is educational and not medical advice. Albiglutide was a prescription medicine and is no longer marketed. Nothing here is a protocol, and the dosing figures below are reported from its former label and trials, not recommendations.

Albiglutide At A Glance

How An Albumin-Fusion GLP-1 Works

Native glucagon-like peptide-1, or GLP-1, is an incretin hormone released from the gut after eating. It increases insulin secretion in a glucose-dependent way, suppresses glucagon, slows gastric emptying and promotes satiety. The problem for drug design is that native GLP-1 is destroyed within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4). For background on the underlying hormone, see what GLP-1 is.

Albiglutide solves the durability problem with structure. It is a recombinant peptide made of two copies of a modified human GLP-1(7-37) sequence fused in tandem to recombinant human albumin, the most abundant protein in blood. A single amino acid substitution at the DPP-4 cleavage site makes the GLP-1 portion resistant to that enzyme, and tethering the active peptide to albumin dramatically slows its clearance.

The result is a molecule that still activates the GLP-1 receptor but circulates for days rather than minutes. The reported plasma half-life is roughly five days, with pharmacokinetic studies describing terminal estimates in the range of about five to eight days depending on the analysis. That is what allowed once-weekly subcutaneous dosing. If you want to understand why half-life dictates dosing frequency across this class, the peptide half-life explainer covers the principle in general terms.

Dosing As Reported By The Label

Because albiglutide was a fully approved product, its dosing is documented in the FDA prescribing information rather than reconstructed from research-market anecdote. These figures are historical and descriptive only.

The Tanzeum label described a recommended starting dose of 30 mg once weekly by subcutaneous injection into the abdomen, thigh or upper arm, with the option to increase to 50 mg once weekly if the glycemic response was inadequate. The product was supplied as a reconstituted pen. If a dose was missed, the label advised administering it within three days. These are reference figures from a discontinued label and are not a recommendation to use or compound the drug.

What The Evidence Showed

Albiglutide reached approval on the strength of the Phase 3 HARMONY program, a set of eight trials involving more than 5,000 patients that compared the drug against placebo and against commonly used type 2 diabetes therapies such as metformin, glimepiride, pioglitazone and insulin. The program supported its glucose-lowering effect and its once-weekly profile.

The most important single study was HARMONY Outcomes (NCT02465515), a double-blind, randomized, placebo-controlled cardiovascular outcomes trial in 9,463 participants with type 2 diabetes and established cardiovascular disease, published in The Lancet in 2018. Over a median follow-up of about 1.6 years, albiglutide reduced the risk of major adverse cardiovascular events by a reported 22 percent relative to placebo. That placed it among the GLP-1 receptor agonists with a demonstrated cardiovascular benefit signal.

The honest limitation is that this evidence is now historical. The drug is not available, so HARMONY Outcomes is most useful as confirmation that the GLP-1 class can lower cardiovascular risk, rather than as guidance for current therapy. It is also worth noting what albiglutide did not do well: its weight-loss and glucose-lowering effects were generally weaker than several competitors, which is central to understanding its withdrawal.

Why It Sits In The Weight-Loss Conversation But Was Not A Weight-Loss Drug

Albiglutide is frequently grouped with weight-loss peptides because it shares the GLP-1 mechanism that drives appetite suppression in drugs like semaglutide and liraglutide (Saxenda). In practice, however, albiglutide was never approved for weight management, and its observed weight reduction was modest. The albumin-fusion design that gave it a long half-life may also have limited its penetration into appetite-regulating brain regions, which is one proposed reason its weight effect lagged behind smaller GLP-1 molecules.

This is a useful distinction when reading GLP-1 for weight loss material. Belonging to the GLP-1 class does not guarantee strong weight effects. Potency, receptor engagement and central nervous system exposure differ across the class, which is why a current GLP-1 drugs list ranks members very differently for weight outcomes.

Safety Issues

Albiglutide carried the safety framework typical of its class, documented in its former FDA label.

These overlap heavily with current GLP-1 side effects, which is expected given the shared receptor target. The boxed warning and medullary thyroid carcinoma contraindication remain class-wide features today.

How To Evaluate A Claim About Albiglutide

Because albiglutide is no longer sold, any vendor or website offering "albiglutide peptide" deserves direct scrutiny. Ask a few questions.

First, is the source acknowledging that the drug was withdrawn? A page that presents albiglutide as a current, purchasable therapy is ignoring the single most important fact about it.

Second, is it conflating the GLP-1 class with weight loss? Albiglutide was a diabetes drug with weak weight effects, so weight-loss marketing built around it is misleading.

Third, is it citing the actual evidence base, meaning the HARMONY trials, the Lancet outcomes paper and the FDA label, rather than secondary blog summaries?

Fourth, is it implying that withdrawal meant the drug was unsafe? The manufacturer described the decision as commercial, driven by competition from more potent agents like tirzepatide (Mounjaro) and high-efficacy GLP-1 options, not by a safety recall.

For broader orientation on this entire category, the overviews of peptides for weight loss and what peptides are provide the wider framing.

Bottom Line

Albiglutide was a legitimate, approved once-weekly GLP-1 receptor agonist with a clever albumin-fusion design, a long half-life and a positive cardiovascular outcomes trial in HARMONY Outcomes. By the usual standards of evidence, it worked.

It is also gone. GlaxoSmithKline withdrew Tanzeum and Eperzan from the worldwide market in 2018 for commercial reasons, as newer GLP-1 receptor agonists offered stronger glucose and weight effects. For today's reader, albiglutide is best understood as history and as a reminder that approval and survival in the market are two different things. It is not a current treatment, not a weight-loss peptide, and not something to source from the research-chemical market.

References

1. U.S. Food and Drug Administration. Tanzeum (albiglutide) prescribing information.

2. Drugs.com FDA Approval History. Tanzeum (albiglutide) FDA approval history.

3. Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet, 2018.

4. ClinicalTrials.gov. Effect of Albiglutide on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus (Harmony Outcomes), NCT02465515.

5. LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases. Albiglutide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.

6. Trujillo JM, Nuffer W. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Preference and Adherence, 2014.

7. GlaxoSmithKline. GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum (albiglutide).

8. GlaxoSmithKline. Positive results from Harmony Outcomes study of albiglutide published in The Lancet.

9. U.S. Food and Drug Administration. Tanzeum (albiglutide) label with boxed warning, thyroid C-cell tumors.